An advisory panel for the Food and Drug Administration (FDA) recently voted to ease restrictions on four specific peptide compounds. This recommendation could lead to wider public access to these substances, which are reportedly promoted by wellness influencers.
The panel's decision was made despite objections from agency scientists, who have described the peptides as poorly understood. Additionally, reports indicate that some members of the advisory panel have ties to the peptide industry.
The Trump Administration's FDA is now reviewing the panel's vote regarding these compounds. This is a developing story and will be updated as details emerge.
